SEC EDGAR Filings

8-K - NKGen Biotech, Inc. - 1.01 / 2.03 / 3.02 / 5.03 / 9.01

Filed: 2026-04-21 AccNo: 0001213900-26-046267 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

查看原文来源主页查看事件簇按来源查看

发布时间04/21 21:20 UTC

首次发现04/21 21:25 UTC

热度106.0

重要度72

情绪-0.04

站内整理正文

优先显示结构化正文；如果正文还未抽出，则回退到摘要。

sec_edgar_index_v1 · 1228 字符

Form 8-K - Current report: SEC Accession No. 0001213900-26-046267

Filing Date: 2026-04-21

Accepted: 2026-04-21 17:20:15

Documents: 21

Period of Report: 2026-04-15

Items: Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

NKGen Biotech, Inc. (Filer) CIK : 0001845459 (see all company filings) EIN. : 000000000 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-40427 | Film No.: 26880624 SIC : 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)

1 | CURRENT REPORT | ea0286919-8k_nkgen.htm iXBRL | 8-K

2 | AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF NKGEN BIOTECH, INC | ea028691901ex3-1.htm | EX-3.1

3 | SECURED CONVERTIBLE LOAN AGREEMENT, DATED APRIL 15, 2026, BY AND AMONG NKGEN BIO | ea028691901ex10-1.htm | EX-10.1

4 | SECURED CONVERTIBLE PROMISSORY NOTE, DATED APRIL 15, 2026, ISSUED BY NKGEN BIOTE | ea028691901ex10-2.htm | EX-10.2